title: Intraocular pressure outcomes after endophthalmitis associated with glaucoma surgery.
abstract: OBJECTIVE
  To determine long-term intraocular pressure (IOP) outcomes and risk factors for failure of IOP control in patients with previous glaucoma surgery that was complicated with infectious endophthalmitis.
  
  
  METHODS
  Retrospective case series of 12 patients with previous glaucoma surgery that presented with infectious endophthalmitis to the University Hospital, Newark, NJ between 1995 and 2006. IOP control failure was stratified into 2 groups: IOP of ≥22 mm Hg and IOP ≥16 mm Hg at 3 consecutive follow-up visits. A Kaplan-Meier survival analysis was used to determine failure rate and Cox proportional hazards model to analyze effects of pertinent variables on survival. P values <0.05 were considered statistically significant.
  
  
  RESULTS
  Twelve patients that had previously undergone glaucoma surgery (8 trabeculectomies and 4 bleb revisions) and were complicated with infectious endophthalmitis were identified. Mean follow-up time was 43.7 months (range, 10 to 98 mo). Of 12 patients, 9 (75%) failed, 2 (17%) consistently maintained IOP<22 mm Hg, and 1 (8%) maintained IOP<16 mm Hg during the follow-up period. Median survival time was 9.25 months. Age of the subject 65 years and older (P=0.0002) was associated with increased risk of IOP failure, whereas initial treatment selection with vitrectomy did not. Six patients required additional glaucoma surgery during the follow-up period.
  
  
  CONCLUSIONS
  IOP control after resolution of endophthalmitis in patients with previous glaucoma surgery was maintained in only 25% of cases. Half the patients required additional glaucoma surgery.
authors.affiliation: *Institute of Ophthalmology and Visual Science †Department of Preventive Medicine & Community Health, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ.
authors.forename: Rana J
authors.initials: RJ
authors.lastname: Mady
authors.forename: Bart K
authors.initials: BK
authors.lastname: Holland
authors.forename: Neelakshi
authors.initials: N
authors.lastname: Bhagat
authors.forename: Marco A
authors.initials: MA
authors.lastname: Zarbin
authors.forename: Robert D
authors.initials: RD
authors.lastname: Fechtner
authors.forename: Albert S
authors.initials: AS
authors.lastname: Khouri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000302:isolation & purification; D003131:Combined Modality Therapy; D009877:Endophthalmitis / Q000382:microbiology / Q000503:physiopathology* / Q000628:therapy; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D005901:Glaucoma / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012086:Reoperation; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014065:Tonometry, Ocular; D014130:Trabeculectomy / Q000009:adverse effects*; D014821:Vitrectomy; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents